Danaher Aktie
WKN: 866197 / ISIN: US2358511028
22.04.2025 12:24:14
|
Danaher Q1 Results Down, Beats Market; Sees Higher Core Revenues In Q2, Backs FY25 View; Stock Up
(RTTNews) - Danaher Corp. (DHR), while reporting weak first-quarter results, but above market estimates, on Tuesday issued outlook for second-quarter revenue and fiscal 2025 earnings. Further, the company maintained annual core revenue growth view.
In pre-market activity on the NYSE, the life sciences and diagnostics company's shares were gaining around 2.8 percent to trade at $190.06.
For the second quarter 2025, the company anticipates that adjusted core revenue will grow low-single digits year-over-year.
For full year 2025, the company expects adjusted net earnings per share in the range of $7.60 to $7.75.
The Wall Street analysts on average expect the company to report earnings of $7.67 per share. Analysts' estimates typically exclude special items.
Further, the firm continues to expect adjusted core revenue for the year to grow approximately 3 percent year-over-year.
In its first quarter, net earnings fell to $954 million from last year's $1.09 billion. Earnings per share declined to $1.32 from $1.45 a year ago.
Adjusted net earnings per share were $1.88, compared to $1.92 last year. The analysts expected the company to report earnings of $1.64 per share.
Revenues decreased 1 percent to $5.74 billion from $5.80 billion in the prior year. Adjusted core revenue was flat year-over-year. Analysts expected revenues of $5.59 billion for the quarter.
Rainer Blair, President and Chief Executive Officer, stated, "Revenue, earnings, and cash flow exceeded our expectations in the first quarter-highlighted by continued momentum in bioprocessing and better-than-expected respiratory demand in our molecular diagnostics business."
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Danaher Corp.mehr Nachrichten
22.04.25 |
Positive Danaher-Zahlen beflügeln auch Aktien von Sartorius, Stedim und EVOTEC (dpa-AFX) | |
21.04.25 |
S&P 500-Wert Danaher-Aktie: So viel Verlust hätte ein Danaher-Investment von vor 3 Jahren eingefahren (finanzen.at) | |
21.04.25 |
Ausblick: Danaher gewährt Anlegern Blick in die Bücher (finanzen.net) | |
14.04.25 |
S&P 500-Papier Danaher-Aktie: So viel Verlust hätte ein Danaher-Investment von vor einem Jahr eingefahren (finanzen.at) | |
07.04.25 |
S&P 500-Titel Danaher-Aktie: So viel hätte eine Investition in Danaher von vor 10 Jahren abgeworfen (finanzen.at) | |
07.04.25 |
Erste Schätzungen: Danaher präsentiert das Zahlenwerk zum abgelaufenen Jahresviertel (finanzen.net) | |
31.03.25 |
S&P 500-Papier Danaher-Aktie: So viel Gewinn hätte ein Investment in Danaher von vor 5 Jahren eingefahren (finanzen.at) | |
24.03.25 |
S&P 500-Titel Danaher-Aktie: So viel Verlust wäre bei einem Investment in Danaher von vor 3 Jahren angefallen (finanzen.at) |
Analysen zu Danaher Corp.mehr Analysen
Aktien in diesem Artikel
Danaher Corp. | 173,40 | 0,56% |
|